NURIX THERAPEUTICS
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad ... class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
NURIX THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2012-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.nurixtx.com
Total Employee:
251+
Status:
Active
Contact:
415-660-5320
Email Addresses:
[email protected]
Total Funding:
370.9 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS Google Google Maps API Google Cloud Apple Mobile Web App Capable
Similar Organizations
Aadi Bioscience
Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Acumen Pharmaceuticals
Acumen is developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
ALung Technologies
ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Axikin Pharmaceuticals
Axikin Pharmaceuticals develops small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases.
Better Therapeutics
Better Therapeutics develops prescription software for treating cardiometabolic diseases.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
CalciMedica
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Carmell Therapeutics
Carmell develops technology for producing biologically-active plastics from blood plasma for treating bone and connective tissue injuries.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
DiscGenics
Regenerative Cell Therapy for Chronic Back Pain.
EnGeneIC
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
ExcepGen
ExcepGen is solving fundamental underlying problems in drug discovery to create a new generation of therapeutics.
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
Gelifex
Gelifex develops implants for use in relieving pain and restoring motion to patients suffering from degenerative disc disease.
HepaRegeniX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Intercept Pharmaceuticals
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
Life Biosciences
Life Biosciences is a developer of drugs designed to promote longevity and find treatments for age-related diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Mobilion Systems
MOBILion Systems specializes in identifying and analyzing challenging molecules that other instruments so far have failed to detect.
Mogrify
Mogrify® will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.
Abliva AB
Abliva develops medicines for the treatment of primary mitochondrial diseases.
Noveome Biotherapeutics
Noveome Biotherapeutics focuses on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
Nutshell Therapeutics
Inventing small molecule in the realm of drug discovery fostered by protein dynamics.
Ocelot Bio
Ocelot Bio brings new treatment options to patients with severe liver disease.
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
Seranova Bio
Seranova Bio develops companion diagnostics or therapeutics to treat autoimmune disease or other autoantibody-driven diseases.
Signum Biosciences
Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Vanquish Oncology
Vanquish Oncology develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Virta Health
Virta delivers a clinically-proven treatment to reverse type 2 diabetes and other chronic metabolic diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Redmile Group
Redmile Group investment in Private Equity Round - Nurix Therapeutics
Boxer Capital
Boxer Capital investment in Private Equity Round - Nurix Therapeutics
The Column Group
The Column Group investment in Private Equity Round - Nurix Therapeutics
Foresite Capital
Foresite Capital investment in Private Equity Round - Nurix Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Private Equity Round - Nurix Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Private Equity Round - Nurix Therapeutics
Wellington Management
Wellington Management investment in Private Equity Round - Nurix Therapeutics
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Private Equity Round - Nurix Therapeutics
The Column Group
The Column Group investment in Series B - Nurix Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series B - Nurix Therapeutics
Official Site Inspections
http://www.nurixtx.com Semrush global rank: 1.92 M Semrush visits lastest month: 11.37 K
- Host name: 172.179.197.104.bc.googleusercontent.com
- IP address: 104.197.179.172
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Nurix Therapeutics"
About - Nurix
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new …See details»
Home | Nurix
Our innovative pipeline focuses the power of our platform to address the unmet needs of patients with cancer and inflammatory diseases. Our goal is to empower the body to fight disease using small molecule drugs to activate or inhibit the …See details»
Scientific Resources - Nurix
Nurix’s dedicated scientists are changing the landscape of cancer treatment. Learn more about our leading-edge research and drug development technology by exploring our presentations, videos, and mechanisms of action.See details»
Nurix Therapeutics Presents Positive Results from Ongoing Clinical ...
SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Nurix Therapeutics - Crunchbase Company Profile
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs. Nurix Therapeutics reported revenue growth in Q1 Fiscal 2024 despite missing earnings predictions.See details»
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial …
SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Nurix Therapeutics Presents Preclinical Data from Two …
Nov 17, 2024 · GS-6791 is a selective, orally bioavailable degrader of interleukin-1 receptor-associated kinase 4 (IRAK4), which is being developed in collaboration with Gilead Sciences …See details»
Nurix Therapeutics Receives PRIME Designation from the …
SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Nurix Therapeutics Expands Its Board of Directors with the …
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Scientific Advisory Board | Nurix - nurixtx.com
Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for cancer. Nurix was founded by a team of internationally renowned experts in the …See details»
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for …
SAN FRANCISCO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation …See details»
Investors - Nurix Therapeutics, Inc.
Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The …See details»
Pipeline - Nurix
Drug discovery alliances with Gilead Sciences, Sanofi, and Pfizer further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders and Degrader …See details»
Nurix Therapeutics Receives U.S. FDA Fast Track Designation
Jan 16, 2024 · --Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory …See details»
Nurix Therapeutics Expands Its Board of Directors with the …
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Nurix Therapeutics Presents Positive Results from the Ongoing …
Oct 19, 2024 · NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial. …See details»
Nurix Therapeutics Presents Positive Results from the Ongoing …
SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation …See details»
Clinical Resources - Nurix
Consistent with Nurix’s mission to bring innovative, safe and effective medicines to patients with serious or life-threatening illnesses or conditions, we are focused on enrolling and conducting …See details»
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual ...
3 days ago · Contact. 1700 Owens Street, Suite 205 San Francisco, CA 94158. Direct: 415-660-5320 Fax: 415-525-4200. [email protected]See details»
Nurix Therapeutics Receives PRIME Designation from the …
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate …See details»